- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02070705
DCE MRI in Patients With Pancreatic Cancer
The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Assess the ability of DCE-MRI to identify the presence of pancreatic cancer in patients at high risk for hereditary pancreatic cancer.
II. Assess the ability of DCE-MRI to identify the presence of pancreatic cancer in patients with cystic lesions of the pancreas.
III. Assess the ability of DCE-MRI to accurately predict tumor margins in patients who have undergone chemotherapy for pancreatic cancer.
IV. Obtain DCE-MRI scans of from healthy volunteers (Group 4), to establish baseline imaging parameters of the normal, non-diseased pancreas for use as a comparator to affected pancreata.
SECONDARY OBJECTIVE:
I. Clinical factors associated with the presence of pancreatic cancer will be assessed in each of the three experimental groups, including disease free survival and overall survival.
II. Additional MRI pulses sequences (e.g. MR fingerprinting, etc.) will be acquired for the assessment of tissue contrast before and after the administration of contrast agents.
OUTLINE: Patients are assigned to 1 of 4 groups.
ARM I (High-risk for familial or hereditary pancreatic cancer): Patients undergo DCE MRI yearly for a minimum of 3 scans.
ARM II (Intraductal papillary mucinous neoplasms [IPMN]): Patients undergo DCE MRI prior to surgery for resection of IPMN.
ARM III (Pancreatic cancer): Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection. Patients currently undergoing neoadjuvant therapy or who have already completed neoadjuvant therapy that were unable to undergo imaging at baseline and are now proceeding to resection will have one DCE MRI scan prior to surgical resection.
ARM IV (Healthy volunteers): Patients undergo a single DCE MRI examination.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- OHSU Knight Cancer Institute
-
Contact:
- Alexander S. Guimaraes
- Phone Number: 503-494-4254
-
Principal Investigator:
- Alexander S. Guimaraes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ALL PARTICIPANTS: A negative serum or urine pregnancy test for woman of childbearing potential
- ALL PARTICIPANTS: Ability to understand and the willingness to sign a written informed consent document
- GROUPS 1, 2, AND 3: "All participants" described above
- GROUPS 1, 2, AND 3: Must be consented for the Oregon Pancreatic Tumor Registry (OPTR)
GROUPS 1, 2, AND 3: Group 1: participants identified as being high-risk for familial or hereditary pancreatic cancer, and must conform to one or more of the following requirements:
- Have a strong family history of pancreatic cancer; this is defined as pancreatic cancer occurring in one first- degree relative and two other relatives, or two first- degree relatives; or,
- Have a known high-risk genetic syndrome (e.g., BRCA 1&2, STK11, CDNK2A, PRSS1, and MSH 2&6)
- GROUPS 1, 2, AND 3: Group 2 participants identified as having IPMN on standard radiographic imaging that meets criteria for resection based on symptoms or on conventional imaging (computed tomography [CT] or MRI) findings
- GROUPS 1, 2, AND 3: Group 3 participants must have pathologically- confirmed pancreatic adenocarcinoma, with or without the need for neoadjuvant chemotherapy prior to surgical resection.
- HEALTHY VOLUNTEERS (Group 4): Must meet inclusion criteria for "all participants" described above
HEALTHY VOLUNTEERS (Group 4): Group 4 participants must have no history of cancer, pancreatic disease, or family history of pancreatic cancer.
- Family history will be defined as pancreatic cancer occurring in one first-degree relative and two other relatives, or two first-degree relatives
Exclusion Criteria:
- Participants unable or unwilling to give written, informed consent or to undergo MRI imaging
- Participants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytol
- Participants with concurrent clinical diagnosis, evidence of suspected hemochromatosis, or other diseases of iron metabolism (i.e., iron overload)
- Cirrhosis, cardiomyopathy, restrictive heart disease, or bronzing of the skin
- Pregnant women are excluded from this study because there is an unknown, but potential risk, for adverse events, as small animal trials have linked ferumoxytol administration (at very high doses) to birth defects (e.g., soft-tissue malformations and decreased fetal weights); it is not known whether ferumoxytol is present in human milk; breastfeeding, however, should be discontinued if the mother receives ferumoxytol while nursing
- Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
- Participants with diagnosis of renal insufficiency or glomerular filtration rate (GFR) < 60 ml/min/1.73m^2
- Adult patients who require monitored anesthesia for MRI scanning
- Participants with any contraindications to gadolinium-based contrast agents
- Participants who have a contraindication for MRI (e.g. metal in their bodies, a cardiac pacemaker, or other incompatible device), or are severely agitated or claustrophobic. (For patients that are eligible but there is a concern of metal in their bodies, the will be given the option if interested to have a x-ray completed prior to study enrollment to determine if they can proceed with the study MRI. Patients with a concern of metal in their bodies that don't agree to a x-ray will not be enrolled into the study.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (High-risk for familial/hereditary pancreatic cancer)
Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
|
Given IV
Other Names:
Undergo DCE MRI
Other Names:
|
Experimental: Arm II (IPMN)
Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
|
Given IV
Other Names:
Undergo DCE MRI
Other Names:
|
Active Comparator: Arm IV (Healthy volunteers)
Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
|
Given IV
Other Names:
Undergo DCE MRI
Other Names:
|
Experimental: Arm III (Pancreatic cancer)
Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies.
For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection.
Patients currently undergoing neoadjuvant therapy or who have already completed neoadjuvant therapy that were unable to undergo imaging at baseline and are now proceeding to resection will have one DCE MRI scan prior to surgical resection.
|
Given IV
Other Names:
Undergo DCE MRI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of pancreatic cancer (yes or no) for patients that are either at high risk for hereditary pancreatic cancer (Group I)
Time Frame: Up to 5 years
|
Descriptive statistical analysis will be conducted for primary endpoints.
|
Up to 5 years
|
Presence of pancreatic cancer (yes or no) for patients with cystic lesions of the pancreas (Group II)
Time Frame: Up to 5 years
|
Descriptive statistical analysis will be conducted for primary endpoints.
|
Up to 5 years
|
Change in tumor margins in patients who have undergone chemotherapy for pancreatic cancer (Group III)
Time Frame: Baseline to up to 2 years
|
The change of dynamic contrast enhanced magnetic resonance imaging (DCE MRI) parameters from baseline will be correlated with the tumor margins determined by pathological specimen following surgical resection through linear regression model.
|
Baseline to up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free survival (Group I)
Time Frame: Time of enrollment to time of diagnosis, assessed up to 5 years
|
Kaplan-Meier method will be used to estimate the survival distribution for disease free survival.
The estimated median and 95% confidence interval will be computed.
|
Time of enrollment to time of diagnosis, assessed up to 5 years
|
Disease free survival (Group II)
Time Frame: Time of surgical resection to time of disease recurrence, if applicable, assessed up to 5 years
|
Kaplan-Meier method will be used to estimate the survival distribution for disease free survival.
The estimated median and 95% confidence interval will be computed.
|
Time of surgical resection to time of disease recurrence, if applicable, assessed up to 5 years
|
Disease free survival (Group III)
Time Frame: Time of surgical resection to time of recurrence, assessed up to 5 years
|
Kaplan-Meier method will be used to estimate the survival distribution for disease free survival.
The estimated median and 95% confidence interval will be computed.
|
Time of surgical resection to time of recurrence, assessed up to 5 years
|
Overall survival (Group I)
Time Frame: Time of surgical resection to time of death, assessed up to 5 years
|
Kaplan-Meier method will be used to estimate the survival distribution for overall survival.
The estimated median and 95% confidence interval will be computed.
|
Time of surgical resection to time of death, assessed up to 5 years
|
Overall survival (Group II)
Time Frame: Time of surgical resection to time of death, assessed up to 5 years
|
Kaplan-Meier method will be used to estimate the survival distribution for overall survival.
The estimated median and 95% confidence interval will be computed.
|
Time of surgical resection to time of death, assessed up to 5 years
|
Overall survival (Group III)
Time Frame: Time of surgical resection to time of death, assessed up to 5 years
|
Kaplan-Meier method will be used to estimate the survival distribution for overall survival.
The estimated median and 95% confidence interval will be computed.
|
Time of surgical resection to time of death, assessed up to 5 years
|
Surgical pathological diagnosis and T & N stage according to the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system (Group II)
Time Frame: At time of surgery
|
Will be assessed as potential confounders or effect modifiers in the model.
Will report c-statistics for each model.
|
At time of surgery
|
Surgical pathological diagnosis and T & N stage according to the AJCC TNM staging system (Group III)
Time Frame: At time of surgery
|
Will be assessed as potential confounders or effect modifiers in the model.
Will report c-statistics for each model.
|
At time of surgery
|
Resection margin status (R0, R1 or R2) (Group III)
Time Frame: At time of surgery
|
Will be assessed as potential confounders or effect modifiers in the model.
Will report c-statistics for each model.
|
At time of surgery
|
DCE- MRI imaging parameters (Group I)
Time Frame: Up to 5 years
|
The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.
|
Up to 5 years
|
DCE- MRI imaging parameters (Group II)
Time Frame: Once prior to surgery
|
The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.
|
Once prior to surgery
|
DCE- MRI imaging parameters (Group III)
Time Frame: Up to 5 years
|
The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.
|
Up to 5 years
|
DCE- MRI imaging parameters and descriptional analysis of normal pancreas DCE- MRI images (Group IV)
Time Frame: Once at time of enrollment
|
The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.
|
Once at time of enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexander Guimaraes, OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Pancreatic Neoplasms
- Neoplasms, Cystic, Mucinous, and Serous
- Pancreatic Intraductal Neoplasms
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Ferrosoferric Oxide
Other Study ID Numbers
- IRB00009694 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2014-00270 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- MR00045736
- CR00022704
- K08EB012859 (U.S. NIH Grant/Contract)
- U01CA278923 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on Ferumoxytol
-
Michael IvNational Cancer Institute (NCI)WithdrawnChildhood Brain NeoplasmUnited States
-
Allegheny Singer Research Institute (also known...Active, not recruitingLiver Neoplasms | Hepatocellular Carcinoma | Liver Metastases | Liver Cancer | Liver Carcinoma | Hepatocellular Cancer | Hepatic Cirrhosis | Hepatic Carcinoma | Hepatic AtrophyUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Radiological Society of North AmericaTerminatedStage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Locally Advanced Rectal CarcinomaUnited States
-
Michael IvCompletedBrain Injury | Brain Cancer | Brain Tumors | Primary Brain Neoplasm | Ischemic Cerebrovascular Accident | Central Nervous System Degenerative Disorder | Central Nervous System Infectious Disorder | Central Nervous System Vascular Malformation | Hemorrhagic Cerebrovascular AccidentUnited States
-
Dana-Farber Cancer InstituteWithdrawn
-
AMAG Pharmaceuticals, Inc.UnknownPeripheral Arterial Disease (PAD)United States
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States
-
University of EdinburghRoyal Brompton & Harefield NHS Foundation Trust; Royal Infirmary of Edinburgh; Golden Jubilee National HospitalCompletedMyocarditis | Healthy Volunteers | Cardiac Transplant | Cardiac SarcoidUnited Kingdom
-
Jason GagliaHarvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious...Unknown